CEACAM6 and cancer: As such, the data in Figure 3 and Figure 4 echoed each other and demonstrated that in the presence of the antibody (anti-CEACAM6) produced by the hybridoma cells in both the in vitro and in vivo setting, the cancer cell lines with CEACAM6 receptors such as A549 and MDA-MB-468 registered a reduction in overall cellular viability as opposed to the cancer cell line PC 3, which does not possess any antigen sites [30].